QRD Pharma

QRD Pharma

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

QRD Pharma is a privately held, revenue-generating contract research organization (CRO) founded in 2022 and based in Warrington, Pennsylvania. The company provides specialized analytical services—including bioanalysis, chiral separation, and DMPK—to pharmaceutical and biotech clients, leveraging techniques like LC-MS and SFC. It has demonstrated rapid growth, expanding its lab footprint and building a diverse client base that ranges from startups to top-tier pharmaceutical companies, with a strong emphasis on data quality and fast turnaround times.

Drug Delivery

Technology Platform

GLP-compliant LC-MS bioanalysis, chiral analysis using Supercritical Fluid Chromatography (SFC), derivatization, and chiral columns, with expanding in vitro DMPK capabilities.

Opportunities

Growth is driven by increasing outsourcing of specialized bioanalytical work by pharma and biotech firms.
The company's niche expertise in chiral analysis using SFC and its expansion into DMPK services present opportunities to capture more of the early-stage drug discovery value chain and serve a broader range of client needs.

Risk Factors

Key risks include dependence on the cyclical R&D spending of biopharma clients, intense competition from both large global CROs and niche specialists, and operational risks related to maintaining stringent GLP compliance, data integrity, and talent retention in a competitive labor market.

Competitive Landscape

QRD Pharma competes in the fragmented bioanalytical CRO market against large, full-service global CROs (e.g., LabCorp, IQVIA) and many smaller, specialized labs. Its differentiation is based on agility, deep expertise in chiral separations using SFC, and a focus on quality and fast turnaround times for a client base ranging from startups to large pharma.